# Vemlidy (tenofovir alafenamide fumarate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tenofovir-alafenamide

> The FDA approved Vemlidy (tenofovir alafenamide fumarate), sponsored by GILEAD SCIENCES, INC. (GILD), on November 10, 2016.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Vemlidy (tenofovir alafenamide fumarate) |
| Codes |  |
| Sponsor | GILEAD SCIENCES, INC. (GILD) https://sec-api.dev/companies/gild/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### November 10, 2016: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208464 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20161110, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22

### February 4, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208464 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20200204, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22

### August 18, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208464 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20200818, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22
- openFDA Drugs@FDA: "NDA208464 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20200818, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22

### October 17, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208464 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20221017, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22

### March 27, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208464 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20240327, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22
- openFDA Drugs@FDA: "NDA208464 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20240327, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tenofovir-alafenamide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vemlidy (tenofovir alafenamide fumarate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tenofovir-alafenamide

```bibtex
@misc{secapidev_pdufa_tenofovir_alafenamide_20261116,
  title        = {Vemlidy (tenofovir alafenamide fumarate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tenofovir-alafenamide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tenofovir_alafenamide_20261116","title":"Vemlidy (tenofovir alafenamide fumarate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tenofovir-alafenamide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
